Recursion cuts nearly half of its pipeline

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, there’s been a lot of discussion lately about how the U.S. can stay competitive in science, biomedical innovation, and drug development. We’ve got several pieces of news relevant to that issue today.

Read the rest…